Browse the evidence

The report includes recommendations on the minimum dietary energy intake from carbohydrates.

Practitioners should consider the recommended minimum dietary energy intake from carbohydrates in dietary planning.

Diabetes, obesity and cardiorenal/metabolic disease often occur in the same patient.

Healthcare providers should be aware of the interconnectedness of these conditions in patients.

Early intensive combination intervention can prevent disease progression and events.

Implementing early and intensive interventions may improve patient outcomes.

Suboptimal metabolic control has not improved in past 20 years despite new medications.

There is a need for improved strategies to manage metabolic control in patients.

GLP-1 agonists have drawbacks in treating obesity.

Practitioners should be aware of the limitations of GLP-1 agonists in obesity treatment.

An alternative approach to GLP-1 agonist treatment includes long-term lifestyle programming.

Incorporating lifestyle changes alongside GLP-1 treatment may enhance effectiveness.

The approach of 'Food Is Medicine' is suggested to address obesity burdens.

Utilizing appropriate food choices can be a key strategy in obesity management.

There is increased recognition that AAS are commonly used illicitly to enhance performance and appearance in several segments of the population.

Awareness of AAS misuse is crucial for health professionals and athletes alike.

Ultrasonography is recommended as the initial screening tool for hepatic steatosis in Latin America.

Practitioners should use ultrasonography for initial screening of MASLD patients.

Complete alcohol abstinence is recommended for patients with significant fibrosis.

Practitioners should advise patients with significant fibrosis to abstain from alcohol.

The relationship between saturated and unsaturated fat consumption and coronary heart disease (CHD) risk is controversial and confusing.

Practitioners should be aware of the ongoing debate regarding dietary fat recommendations.

The symposium aimed to summarize key scientific evidence regarding dietary fats and CHD risk.

The symposium provided a platform for discussing scientific evidence on dietary fats.

An increasingly unhealthful lifestyle among the US population has led to an obesity epidemic.

Promoting healthier lifestyle choices is essential to combat the obesity epidemic.

Future clinical trials with other incretin mimetics may further emphasize the importance of an obesity phenotype-based approach in treating HFpEF.

Clinicians should stay informed about upcoming trials that may validate obesity phenotype-based treatments.

Final proof of efficacy for incretin therapies on primary clinical liver outcomes may come from large database analyses.

Future studies should focus on analyzing large datasets to confirm the efficacy of incretin therapies for NAFLD.

Cautious use of tirzepatide is vital due to potential adverse effects and contraindications.

Healthcare providers should monitor patients closely for adverse effects when prescribing tirzepatide.

Further interventional studies involving humans are needed to better understand the role of soy isoflavones in PCOS.

More research is necessary to fully understand how soy isoflavones can be effectively used in treating PCOS.

Strategies in supporting health and performance over a player's career are encouraged.

Organizations should hire qualified nutrition professionals to support players' long-term health.

There is a need to dispel myths about weight-loss medications.

Educating patients and physicians about the realities of weight-loss medications can improve acceptance and usage.

Semaglutide's success in India will depend on affordability, rational prescribing, and integration into preventive care frameworks.

Efforts should focus on making semaglutide accessible and integrating it into broader health strategies.

Further investigations are warranted regarding the effects of GLP-1-based therapies on skeletal muscle.

Practitioners should advocate for more research to better understand the implications of GLP-1 therapies on muscle health.

The conference affirmed the need for a medically meaningful and actionable diagnosis of obesity.

Practitioners should focus on developing actionable diagnostic criteria for obesity.

There is a need for increased nutrition and obesity education.

Practitioners should enhance education efforts regarding nutrition and obesity.

It is important to avoid stigmatizing overweight and obesity in weight management.

Practitioners should be mindful of language and attitudes towards patients with overweight and obesity.